# CANbridge Life Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/canbridge-life-sciences

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.canbridgepharma.com
- Total disclosed funding: $214M
- Latest round: Series E (Dec 1, 2020)
- Investors on record: 19

## About

Established in 2012 and based in Beijing, China, CANbridge Life Sciences, Ltd. operates as a biopharmaceutical company that develops drug candidates and other healthcare products for serious and critical medical conditions. Founder Dr. Xue Qunis the CEO and formerly an executive of Genzyme in the United States and the first general manager of Genzyme China.

The company focuses on the development of cutting-edge technology fields such as innovative bio-targeted drugs for malignant tumors and precision treatments represented by rare diseases. The company is committed to accelerating the development and commercialization of innovative therapies for rare diseases and rare tumors in China and globally to fill the unmet medical needs.

## Funding rounds

- Series E, Dec 1, 2020, $43M — Hudson Bay Capital, Casdin Capital, Hangzhou Tigermed Consulting Company Limited, 3W Fund Management, RA Capital Management, LYFE Capital, Summer Capital, SPDBI, Yaly Capital
- Series D, Feb 18, 2020, $98M — General Atlantic, Hudson Bay Capital, RA Capital Management, YuanMing Capital, Tigermed, Wuxi AppTec Group
- Series C, Aug 1, 2018, $38M — Qiming Venture Partners
- Series C, May 17, 2018 — DNV Capital
- Series B, May 23, 2017, $25M — Qiming Venture Partners, Lapam Capital, YuanMing Capital, Biossom Investment Management, Yanyuan Capital, Wuxi AppTec Group
- Series A, Dec 3, 2014, $10M — Qiming Venture Partners, TF Capital

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B, Series C
- TF Capital — Series A
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series B
- YuanMing Capital (https://capitalatlas.ai/funds/yuanming-capital) — Series B, Series D
- Biossom Investment Management (https://capitalatlas.ai/funds/biossom-investment-management) — Series B
- Yanyuan Capital — Series B
- Wuxi AppTec Group — Series B, Series D
- DNV Capital (https://capitalatlas.ai/funds/dnv-capital) — Series C
- General Atlantic (https://capitalatlas.ai/funds/general-atlantic) — Series D
- Hudson Bay Capital — Series D, Series E
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series D, Series E
- Tigermed (https://capitalatlas.ai/funds/tigermed) — Series D
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series E
- Hangzhou Tigermed Consulting Company Limited — Series E
- 3W Fund Management — Series E
- LYFE Capital — Series E
- Summer Capital — Series E
- SPDBI — Series E
- Yaly Capital — Series E